

Lisa A. Prosser, Ph.D.

Professor of Pediatrics and Communicable Diseases, Medical School and
Professor of Health Management and Policy, School of Public Health
300 North Ingalls St, 6A14, Ann Arbor, MI 48109-5456
lisapros@med.umich.edu

Education and Training

- 09/1995-06/2000 Ph.D. Health Policy (Concentration: Decision Sciences)
Harvard University, Cambridge, MA
- 09/1990-06/1992 M.S. Technology & Policy
Massachusetts Institute of Technology, Cambridge, MA
- 09/1990-06/1992 M.S. Management
MIT Sloan School of Management, Cambridge, MA
- 09/1987-12/1987 Semester Abroad, School of Mathematical Sciences
Queen Mary College, University of London, London, UK
- 08/1984-05/1988 B.A. Mathematics (Concentration: Operations Research)
Cornell University, Ithaca, NY

Academic, Administrative, and Clinical Appointments

Academic Appointments

- 09/2016-present Professor (with tenure), Department of Pediatrics and Communicable
Diseases
University of Michigan, Ann Arbor, MI
- 09/2016-present Professor (secondary), Department of Health Management and Policy
University of Michigan School of Public Health, Ann Arbor, MI
- 09/2016-present Adjunct Professor, Department of Health Policy and Management
Harvard T.H. Chan School of Public Health, Boston, MA
- 09/2013-08/2015 Associate Professor (with tenure), Department of Pediatrics and
Communicable Diseases
University of Michigan, Ann Arbor, MI
- 11/2010-08/2013 Associate Professor, Department of Pediatrics and Communicable
Diseases
University of Michigan, Ann Arbor, MI
- 09/2010-present Research Associate Professor (secondary), Department of Health
Management and Policy

University of Michigan School of Public Health, Ann Arbor, MI

10/2008-10/2010 Research Associate Professor, Department of Pediatrics and Communicable Diseases
University of Michigan, Ann Arbor, MI

10/2008-08/2016 Adjunct Associate Professor, Department of Health Policy and Management
Harvard School of Public Health, Boston, MA

10/2008-06/2012 Lecturer, Department of Population Medicine (formerly Department of Ambulatory Care & Prevention)
Harvard Medical School, Boston, MA

01/2008-09/2008 Research Scientist, Center for Health Services Research
Henry Ford Health System, Detroit, MI

02/2006-04/2009 Assistant Professor (secondary), Department of Health Policy and Management
Harvard School of Public Health, Boston, MA

04/2001-05/2009 Assistant Professor, Department of Ambulatory Care & Prevention
Harvard Medical School, Boston, MA

07/2000-03/2001 Instructor, Department of Ambulatory Care & Prevention
Harvard Medical School, Boston, MA

07/1999-06/2000 Fellow, Department of Ambulatory Care & Prevention
Harvard Medical School, Boston, MA

11/1996-06/2000 Research Assistant, Program for the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA

08/1992-07/1995 Health Care Management Consultant, The Wilkerson Group, New York, NY

06/1991-08/1991 Health Policy Analyst, Abt Associates, Cambridge, MA

08/1988-08/1990 Systems Consultant, Andersen Consulting, Stamford, CT

Related Academic Positions

2018-present Senior Faculty Advisor to the Early Career Faculty Development Council,
Institute for Healthcare Policy and Innovation

| | |
|--------------|---|
| 2013-present | Director, Program in Comparative Effectiveness and Child Health, Child Health Evaluation and Research Center |
| 2010-present | Core Faculty, Decision Sciences and Operations Research Cognate, PhD Program in Health Services Organization and Policy, University of Michigan School of Public Health |
| 2011-2015 | Affiliated Faculty, Risk Science Center, University of Michigan School of Public Health |
| 2011-2016 | Core Faculty, Pediatric Health Services Research Fellowship Program, University of Michigan, Ann Arbor, MI |
| 2008-2010 | Affiliated Faculty, Pediatric Health Services Research Fellowship Program, University of Michigan, Ann Arbor, MI |
| 2008-present | Core Faculty, Child Health Evaluation and Research Unit, Division of General Pediatrics, University of Michigan, Ann Arbor, MI |

Administrative Appointments

| | |
|-----------------|--|
| 07/2015-present | Director, Child Health Evaluation and Research Center, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI |
| 07/2013-06/2015 | Interim Director, Child Health Evaluation and Research Unit, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI |
| 01/2013-06/2015 | Director, Faculty Development, Office of Faculty Affairs, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI |

Research Interests

My research uses methods of decision science and economic evaluation to measure the value of childhood health interventions. Current research topics include the evaluation of long-term health and economic outcomes for childhood interventions using simulation modeling, vaccine policy, and methods for valuing family spillover effects of illness. My applied research on the economic impact of vaccination for herpes zoster and influenza has been used in setting national vaccine policy. I have also contributed to newborn screening policy through my research supporting the Advisory Committee for Heritable Disorders in Newborns and Children. My methodological research focuses on methods for valuing child health for cost-effectiveness analysis and, specifically, the measurement of family spillover effects on quality-of-life for childhood conditions.

Grants

Present and Active

Sponsor and grant number: Centers for Disease Control and Prevention, 1U01 IP000965-01

Title: Joint Initiative in Vaccine Economics, Phase 5

Principal investigator: David Hutton/Lisa Prosser

Inclusive dates: 2015-2019

Role: Co-PI (10%)

Funding amount: \$899,682

Sponsor and grant number: NIDDK, P30DK092926

Title: Michigan Diabetes Research and Training Center (Biostatistics and Economic Modeling Core)

Principal investigator: William Herman

Inclusive dates: 2016-2021

Role: Co-Investigator (5%)

Sponsor and grant number: NIH, U01DE021412

Title: Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings

Principal investigator: Margherita Fontana

Inclusive dates: 2018-2022

Role: Co-Investigator (25%)

Sponsor and grant number: NIH, R01HD086583

Title: Decision-Making for Patients Born with Differences of Sex Development (DSD)

Principal investigator: David Sandberg

Inclusive dates: 2016-2021

Role: Co-Investigator (10%)

Sponsor and grant number: NIDDK, R01DK109995

Title: Population Health Impact of a Self-Insured Employer's Policy Change to Cover Weight Reduction and Diabetes Prevention Interventions for Employees, Dependents, and Retirees with Prediabetes

Principal investigator: William Herman

Inclusive dates: 2016-2020

Role: Co-Investigator (5%)

Sponsor and grant number: NIH, R24HD087149

Title: Building Research Capacity for Firearm Safety among Children

Principal investigator: Marc Zimmerman/Rebecca Cunningham

Inclusive dates: 2017-2022

Role: Co-Investigator (5%)

Sponsor and grant number: MI Dept of Health and Human Services

Title: Michigan Section 298 Pilot Demonstration Evaluation

Principal investigator: Kara Zivin

Inclusive dates: 2017-2020
Role: Co-Investigator (5%)

Sponsor and grant number: NIH
Title: The Lifecycle of Health Data: Policies and Practice
Principal investigator: Sharon Kardia/Jody Platt
Inclusive dates: 2018-2022
Role: Co-Investigator (5%)

Previous Grants

Sponsor and grant number: Patient-Centered Outcomes Research Institute, CE 1304-6598
Title: Improving Patient Decisions about Bariatric Surgery
Principal investigator: Nancy Birkmeyer
Inclusive dates: 2014-2018
Role: Co-Investigator (10%)
Funding amount: \$1,528,671

Sponsor and grant number: Duke/HRSA
Title: HRSA MCHB TASK ORDER (FY16) to Support the ACHDNC
Principal investigator: Alex Kemper
Inclusive dates: 2016-2018
Role: Co-Investigator (10%)

Sponsor and grant number: Agency for Healthcare Research and Quality, R01HS020644
Title: Health and economic outcomes for newborn screening
Principal investigator: Lisa Prosser
Inclusive dates: 2011-2017
Role: Principal Investigator (40%)
Funding amount: \$2,490,854

Sponsor and grant number: Centers for Disease Control and Prevention
Title: Cost Effectiveness Modeling of a New Shingles Vaccine
Principal investigator: Lisa Prosser
Inclusive dates: 2016-2017
Role: Principal Investigator (10%)
Funding amount: \$96,774

Sponsor and grant number: Robert Wood Johnson Foundation
Title: Improving the Efficiency of Newborn Screening from Collection to Test Results
Principal investigator: Beth Tarini
Inclusive dates: 2015-2017
Role: Co-Investigator (5%)
Funding amount: \$350,000

Sponsor and grant number: NIH-DHHS-US; 5 K23 HD070913-05
Title: Brief ED Intervention to Increase Size-Appropriate Child Passenger Restraint Use

Principal investigator: Michelle Macy
Inclusive dates: 2012-2017
Role: Co-Investigator
Funding amount: \$669,600

Sponsor and grant number: Centers for Disease Control and Prevention
Title: Immunization – The Total Burden of Herpes Zoster and Herpes Zoster Pain in the U.S.
Principal investigator: Lisa Prosser
Inclusive dates: 2014-2016
Role: Principal Investigator (10%)
Funding amount: \$150,755

Sponsor and grant number: Patient-Centered Outcomes Research Institute (via Kaiser)
Title: Balancing Treatment Outcomes and Medication Burden among Patients with Symptomatic Diabetic Peripheral Neuropathy (DPN)
Principal investigator: Alyce Adams
Inclusive dates: 2013-2016
Role: Consultant

Sponsor and grant number: NIH/University of California Los Angeles, R01 HD068138
Title: Disorders of Sex Development: Platform for Basic and Translational Research
Principal investigator: David Sandberg, Eric Vilain
Inclusive dates: 2011-2016
Role: Co-Investigator
Funding amount: \$244,067

Sponsor and grant number: NIH/NIDDK, 5P30 DK092926-05
Title: Michigan Center for Diabetes Translational Research (P30)
Principal investigator: William Herman
Inclusive dates: 2011-2016
Role: Co-Investigator (5%)
Funding amount: \$2,519,426

Sponsor and grant number: HRSA (via Duke University)
Title: Discretionary Advisory Committee for Heritable Disorders in Newborns and Children Condition Review Group
Principal investigator: Alex Kemper
Inclusive dates: 2014-2015
Role: Co-Investigator, Site PI (10%)
Funding amount: \$21,929 (subcontract amount)

Sponsor and grant number: NIH/NIDDK, 5P60 DK020572-33
Title: Michigan Diabetes Research and Training Center (MRDTC)
Principal investigator: William Herman
Inclusive dates: 2011-2015
Role: Co-Investigator (5%)
Funding amount: \$1,775,457

Sponsor and grant number: HRSA (via Duke University)
Title: DACHDNC Condition Review Group
Principal investigator: Alex Kemper
Inclusive dates: 2014-2015
Role: Co-Investigator, Site PI (10%)
Funding amount: \$493,338 (subcontract amount)

Sponsor and grant number: Centers for Disease Control and Prevention, 1U01IP00049901
Title: Joint Initiative in Vaccine Economics, Phase 4
Principal investigator: Lisa Prosser
Inclusive dates: 2011-2015
Role: Principal Investigator (25%)
Funding amount: \$899,980

Sponsor and grant number: Agency for Healthcare Research and Quality, U18HS020516
Title: Quality measurement, evaluation, testing, review and implementation consortium (Q-METRIC).
Principal investigator: Gary Freed
Inclusive dates: 2011-2015
Role: Co-Investigator (3%)
Funding amount: \$7,998,239

Sponsor and grant number: HRSA (via Atlas Research)
Title: DACHDNC Condition Review Group
Principal investigator: Alex Kemper
Inclusive dates: 2013-2014
Role: Co-Investigator, Site PI (10%)
Funding amount: \$51,921 (subcontract amount)

Sponsor and grant number: FDA (via Harvard Pilgrim Health Care)
Title: Equipping PRISM for Pandemic Influenza (Medical Countermeasures Initiative)
Principal investigator: Tracy Lieu
Inclusive dates: 2011-2014
Role: Co-Investigator, Site PI (5%)
Funding amount: \$20,375 (subcontract amount)

Sponsor and grant number: National Institute for Nursing Research, R01 NR011880-01
Title: HRQOL impacts of illness on family and caregivers
Principal investigator: Eve Wittenberg, Harvard School of Public Health
Inclusive dates: 2009-2013
Role: Co-Investigator (25%), Subcontract PI
Funding amount: \$475,781

Sponsor and grant number: Centers for Disease Control and Prevention, 200-2005-M-12981
Title: Measuring preferences for quality of life for child maltreatment outcomes
Principal investigator: Derek Brown, RTI International

Inclusive dates: 2008-2012
Role: Co-Investigator (5%)
Funding amount: \$400,000

Sponsor and grant number: Centers for Disease Control and Prevention, U01IP000316-01
Title: TIME: Technology for Immunization Message Enhancement
Principal investigator: Kevin Dombkowski
Inclusive dates: 2009-2012
Role: Co-Investigator (2%)
Funding amount: \$450,000

Sponsor and grant number: Centers for Disease Control and Prevention, 3U01IP000029-03S1
Title: Joint Initiative in Vaccine Economics III
Principal investigator: Tracy Lieu, Harvard Medical School and Harvard Pilgrim Health Care
Inclusive dates: 2007-2011
Role: Co-Investigator
Funding amount: \$1,279,848

Sponsor and grant number: Centers for Disease Control and Prevention, U01IP000029-03S1
Title: Cost-effectiveness of novel H1N1 influenza vaccination in the United States
Principal investigator: Lisa Prosser
Inclusive dates: 2009-2010
Role: Principal Investigator
Funding amount: \$158,650

Sponsor and grant number: Centers for Disease Control and Prevention (via the University of Michigan Prevention Research Center, U48DP001901)
Title: Public values for pandemic H1N1 influenza vaccination-related adverse events
Principal investigator: Lisa Prosser
Inclusive dates: 2009-2010
Role: Principal Investigator
Funding amount: \$147,699

Sponsor and grant number: Centers for Disease Control and Prevention, U01IP000029-03S1
Title: Cost-effectiveness of live attenuated influenza vaccine for children
Principal investigator: Lisa Prosser
Inclusive dates: 2007-2008
Role: Principal Investigator
Funding amount: \$89,381

Sponsor and grant number: Harvard Pilgrim Health Care Foundation, AF000103 DACP Grant Program
Title: Economic barriers to obesity prevention and management in children
Principal investigator: Lisa Prosser
Inclusive dates: 2006-2007
Role: Principal Investigator
Funding amount: \$50,669

Sponsor and grant number: Blue Shield Foundation, 1433883
Title: Combining clinical effectiveness and cost effectiveness
Principal investigator: Stephen Pearson
Inclusive dates: 2006-2007
Role: Co-Investigator
Funding amount: \$430,000

Sponsor and grant number: National Institute of Child Health and Human Development, R01HD050966
Title: Improving primary care to prevent childhood obesity
Principal investigator: Matthew Gillman
Inclusive dates: 2005-2010
Role: Co-Investigator
Funding amount: \$3,102,108

Sponsor and grant number: National Library of Medicine, R21LM008707
Title: Methods for evaluating bioterrorism surveillance systems
Principal investigator: Ken Kleinman
Inclusive dates: 2005-2006
Role: Co-Investigator
Funding amount: \$419,430

Sponsor and grant number: Centers for Disease Control and Prevention
Title: Child maltreatment quality of life measurement tool
Principal investigator: Lisa Prosser
Inclusive dates: 2005-2006
Role: Principal Investigator
Funding amount: \$65,004

Sponsor and grant number: Harvard Pilgrim Health Care, DACP Faculty Grant Program
Title: Valuing children's health: a review of cost-effectiveness analysis for pediatric health interventions
Principal investigator: Lisa Prosser
Inclusive dates: 2005-2006
Role: Principal Investigator
Funding amount: \$27,754

Sponsor and grant number: Centers for Disease Control and Prevention, K01DP000089
Title: Health values and treatment of pediatric type 2 diabetes (K-award, Erinn Rhodes)
Principal investigator: Erinn Rhodes
Inclusive dates: 2004-2007
Role: Consultant

Sponsor and grant number: Centers for Disease Control and Prevention, U01IP000029
Title: Joint Initiative in Vaccine Economics II
Principal investigator: Tracy Lieu

Inclusive dates: 2004-2007
Role: Co-Investigator
Funding amount: \$1,428,261

Sponsor and grant number: National Institute on Deafness and Other Communication Disorders, R01DC005834

Title: Decision analysis of otitis media vaccination strategies (R01)
Principal investigator: Tracy Lieu
Inclusive dates: 2003-2006
Role: Co-Investigator
Funding amount: \$3,102,108

Sponsor and grant number: ELSI/National Human Genome Research Institute, R01HG002085

Title: Expanded newborn screening for metabolic disorders (R01)
Principal investigator: Susan Waisbren
Inclusive dates: 2003-2006
Prosser role: Co-Investigator
Funding amount: \$1,766,844

Sponsor and grant number: PhRMA Foundation

Title: Are managed care decisions consistent with public preferences?
Principal investigator: Lisa Prosser
Inclusive dates: 2002-2003
Role: Principal Investigator
Funding amount: \$60,000

Sponsor and grant number: Agency for Healthcare Research and Quality, U01HS012019

Title: Randomized controlled trial to reduce prescribing errors in hypertension (R01)
Principal investigator: Stephen Soumerai
Inclusive dates: 2001-2004
Role: Co-Investigator
Funding amount: \$568,684

Sponsor and grant number: Centers for Disease Control and Prevention, U01IP000029

Title: Joint Initiative in Vaccine Economics
Principal investigator: Tracy Lieu
Inclusive dates: 2001-2004
Role: Co-Investigator; lead investigator for sub-study: Costs and cost-effectiveness of administering influenza vaccination in non-traditional settings
Funding amount: \$1,294,084

Sponsor and grant number: Centers for Disease Control and Prevention (through Vaccine Safety Datalink)

Title: Economic analysis of strategies to reduce influenza morbidity in children
Principal investigator: Tracy Lieu
Inclusive dates: 2001-2002
Role: Co-Investigator

Funding amount: \$82,565

Sponsor and grant number: Centers for Disease Control and Prevention (through Alliance of Community Health Plans)

Title: Cost-effectiveness of pneumococcal conjugate vaccine

Principal investigator: Tracy Lieu

Inclusive dates: 2000-2002

Role: Co-Investigator

Funding amount: \$200,000

Sponsor and grant number: National MS Society (dissertation fellowship)

Title: Cost-effectiveness of interferon beta-1a, interferon beta-1b and glatiramer acetate in patients with relapsing-remitting multiple sclerosis

Principal investigator: Lisa Prosser (Doctoral student)

Inclusive dates: 1997-1999

Role: Principal Investigator (Doctoral Student)

Funding amount: \$30,000

Honors and Awards

| | |
|-----------|--|
| 2017 | Impact Accelerator Award for public health impact, Institute for Healthcare Policy and Innovation, University of Michigan |
| 2015 | International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research |
| 2005 | Best General Podium Presentation, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting |
| 2002 | 50 th Anniversary Scholars in Medicine Award, Harvard Medical School |
| 1999-2000 | Thomas O. Pyle Fellowship, Harvard Pilgrim Health Care and Harvard Medical School |
| 1999 | National Cholesterol Outcomes Research Excellence (CORE) Award, first place |
| 1998 | Lee B. Lusted Student Prize, Society for Medical Decision Making |
| 1997-1999 | National Multiple Sclerosis Society Doctoral Dissertation Fellowship |
| 1995-1997 | National Library of Medicine Fellowship |
| 1992 | MIT Award in recognition of founding Women in Technology & Policy |
| 1992 | William J. Stewart, Jr., Award for extracurricular leadership at MIT |
| 1991 | Master's Thesis Travel Grant, MIT Program on the Pharmaceutical Industry |
| 1984-1988 | Cornell Tradition Fellowship, Miller Scholarship in Mathematics, Newton North High School Music Department Scholarship, Sons of Italy Scholarship, National Merit Scholarship Semifinalist |

Memberships in Professional Societies

1996-present Member, Academy Health

| | |
|--------------|---|
| | Member, Child Health Interest Group Advisory Committee (2016-present) |
| | Member, Research Insights Advisory Committee (2017- present) |
| 1996-present | Member, Society for Medical Decision Making |
| | Co-Chair, Scientific Review Committee (2008 & 2009 Annual Meetings) |
| | Abstract Reviewer, Annual Meetings (2000-2015) |
| | Trustee (2010 – 2013) |
| | Chair, Publications Committee (2010 – 2013) |
| | Chair, Editor-in-Chief Search Committee, <i>Medical Decision Making</i> (2011-2012) |
| | Member, Silhouette Journal Committee (2015 – present) |
| | Vice President Elect (2015-2016) |
| | Vice President (2016-2017) |
| 2000-present | Member, International Health Economics Association |
| 2001-present | Member, International Society for Pharmacoeconomics and Outcomes Research |
| | Co-Chair, Contributed Workshops (2006 Annual International Meeting) |
| | Abstract Reviewer, Annual Meetings (2002-2011) |
| | Member, Conjoint Analysis Best Practices Task Force (2008 – 2011) |
| 2006-present | Member, American Society of Health Economists |
| | Abstract Reviewer, Annual Meeting (2012) |
| 2012-present | Member, Society for Pediatric Research |
| 2014-present | Member, Academic Pediatric Association |
| 2015-present | Member, American Pediatric Society |

Editorial Positions, Boards, and Peer-Review Service

Editorial Positions

| | |
|--------------|---|
| 2008-present | Editorial Board, <i>Pharmacoeconomics</i> |
| 2011-2012 | Guest Editor, Special Issue on Child Health, <i>Pharmacoeconomics</i> |
| 2017-present | Guest Editor, Special Issue on Family Spillover Effects, <i>Pharmacoeconomics</i> |

Peer-Review Service

| | |
|--------------|--|
| 1997-present | Ad hoc reviewer, <i>Journal of Health Economics</i> |
| 1999 | Ad hoc reviewer, <i>Evaluation and Program Planning</i> |
| 1999 | Ad hoc reviewer, <i>Medical Care</i> |
| 2000 | Ad hoc reviewer, <i>Annals of Internal Medicine</i> |
| 2000 | Ad hoc reviewer, <i>American Journal of Managed Care</i> |
| 2001 | Ad hoc reviewer, <i>Pharmacoeconomics</i> |
| 2001 | Ad hoc reviewer, <i>Future Drugs</i> |
| 2001-present | Ad hoc reviewer, <i>Medical Decision Making</i> |

| | |
|--------------|--|
| 2003 | Ad hoc reviewer, <i>Clinical Therapeutics</i> |
| 2003-present | Ad hoc reviewer, <i>Value in Health</i> |
| 2004-present | Ad hoc reviewer, <i>Vaccine</i> |
| 2004 | Ad hoc reviewer, <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> |
| 2004 | Ad hoc reviewer, <i>American Journal of Managed Care</i> |
| 2004 | Ad hoc reviewer, <i>Pediatrics</i> |
| 2005 | Ad hoc reviewer, <i>Archives of Adolescent Medicine</i> |
| 2005-present | Ad hoc reviewer, <i>The Lancet</i> |
| 2005 | Ad hoc reviewer, <i>Epidemiologic Reviews</i> |
| 2005 | Ad hoc reviewer, <i>Journal of Pediatrics</i> |
| 2006 | Ad hoc reviewer, <i>AHRQ</i> |
| 2006-present | Ad hoc reviewer, <i>Health Affairs</i> |
| 2006 | Ad hoc reviewer, <i>Arch Dermatology</i> |
| 2006 | Ad hoc reviewer, <i>Human Vaccines</i> |
| 2007 | Ad hoc reviewer, <i>Health Policy</i> |
| 2007-present | Ad hoc reviewer, <i>New England Journal of Medicine</i> |
| 2008-present | Ad hoc reviewer, <i>Quality of Life Research</i> |
| 2009-present | Ad hoc reviewer, <i>JAMA</i> |
| 2013 | Ad hoc reviewer, <i>The Patient</i> |
| 2014 | Ad hoc reviewer, <i>Academic Pediatrics</i> |

Teaching

Courses

| | |
|-----------|---|
| 1996-1998 | Teaching Assistant: Management Science Harvard School of Public Health 6 graduate students, 4 hours per week, one-half semester. |
| 1996 | Teaching Assistant: Decision Analysis in Clinical Research Harvard School of Public Health 40 graduate students, 4 hours per week, one-half semester. |
| 1996 | Teaching Assistant: Decision Analysis for Health and Medical Practices Harvard School of Public Health 40 graduate students, 4 hours per week, one-half semester. |
| 1997 | Teaching Assistant: Decision Theory Harvard School of Public Health 8 graduate students, 4 hours per week, one semester. |
| 2003-2005 | Guest Lecturer: Methods for Decision Analysis in Public Health and Medicine Harvard School of Public Health 25 students, 6 hours. |

- 2004-2007 Guest Lecturer: Cost-Effectiveness and Cost-Benefit Analysis for Health Program Evaluation
Harvard School of Public Health
40 graduate students, 6 hours.
- 2006 Primary Instructor: Decision Analysis Methods in Public Health and Medicine
Harvard School of Public Health
25 students, 14 hours per week, one-half semester.
- 2009 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
32 students, 3 lectures, 12 hours.
- 2009 Lecturer: Pediatric Health Services Research Fellowship Methods Seminar
Child Health Evaluation and Research Unit, General Pediatrics
University of Michigan
20 attendees, 1 lecture, 6 hours.
- 2010 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
36 students, 2 lectures, 8 hours.
- 2010 Guest Lecturer: Research on Health Care Delivery, Financing and Policy
Robert Wood Johnson Clinical Scholars Program, University of Michigan
Medical School
15 students, 1 lecture, 5 hours.
- 2010 Guest Lecturer: Social and Administrative Sciences seminar (SOCADMIN 839)
University of Michigan College of Pharmacy
25 students, 1 lecture, 3 hours.
- 2010 Guest Lecturer: Health Care Markets and Public Policies (BE 608)
University of Michigan Ross School of Business
40 students, 1 lecture and take-home case study, 10 hours.
- 2011 Guest Lecturer: Research on Health Care Delivery, Financing and Policy (HHCR 740/741)
Robert Wood Johnson Clinical Scholars Program, University of Michigan
Medical School
15 students, 1 lecture, 5 hours.
- 2011 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
30 students, 3 lectures, 12 hours.

- 2011 Guest Lecturer: Pharmacy Health Care Outcomes (PHAR 540)
University of Michigan College of Pharmacy
100 students, 1 lecture + quiz, 5 hours.
- 2011 Co-Instructor: Doctoral Seminar in Health Services and Systems
Research II(HMP 804)
University of Michigan School of Public Health
7 students, 2 lectures, 8 hours.
- 2012 Guest Lecturer: Research on health Care Delivery, Financing and Policy
(HHCR 740)
Robert Wood Johnson Clinical Scholars Program, University of Michigan
Medical School
15 students, 2 lectures, 8 hours.
- 2012 Guest Lecturer: Pharmacy Health Care Outcomes (PHAR 522)
University of Michigan College of Pharmacy
100 students, 1 lecture + quiz, 5 hours.
- 2012 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
20 students, 2 lectures, 8 hours.
- 2013 Co-Instructor: Economics of Health Management & Policy II (HMP 663)
University of Michigan School of Public Health
100 students, 6 lectures, 60 hours.
- 2013 Co-Instructor: Doctoral Seminar in Health Services and Systems
Research II (HMP 806)
University of Michigan School of Public Health
7 students, 3 lectures, 12 hours.
- 2013 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
30 students, 1 lecture, 4 hours.
- 2013 Guest Lecturer: Pharmacy Health Care Outcomes (PHAR 522)
University of Michigan College of Pharmacy
100 students, 1 lecture + quiz, 5 hours.
- 2014 Co-Instructor: Advanced Topics in Decision Sciences (HMP 680)
University of Michigan School of Public Health
5 students, 2 credits.
- 2014 Co-Instructor: Doctoral Seminar in Health Services and Systems
Research II (HMP 806)

- University of Michigan School of Public Health
6 students, 2 sessions.
- 2014 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
30 students, 1 lecture, 4 hours.
- 2014 Guest Lecturer: Pharmacy Health Care Outcomes (PHAR 522)
University of Michigan College of Pharmacy
100 students, 1 lecture.
- 2015 Co-Instructor: Doctoral Seminar in Health Services and Systems
Research II (HMP 806)
University of Michigan School of Public Health
8 students, 2 sessions, 1 final paper.
- 2015 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
30 students, 1 lecture, 4 hours.
- 2016 Co-Instructor: Doctoral Seminar in Health Services and Systems
Research II (HMP 806), 1 credit course
University of Michigan School of Public Health
6 students, 3 sessions, 1 final paper.
- 2016 Guest Lecturer: Cost-effectiveness Analysis in Health (HMP 610)
University of Michigan School of Public Health
30 students, 1 lecture, 4 hours.
- 2017 Co-Instructor: Doctoral Seminar in Health Services and Systems
Research II (HMP 803), 1 credit course
University of Michigan School of Public Health
7 students, 3 sessions, 1 final paper.

Intramural Invited Presentations

- 2000 Department of Ambulatory Care and Prevention, Harvard Medical School,
seminar:
Patient-specific factors in clinical decision-making: the relationship
between risk attitude and treatment choice in patients with multiple
sclerosis
- 2000 Harvard Center for Risk Analysis, Harvard School of Public Health,
Preference Working Group seminar:
Patient preferences for treatments and health states in multiple sclerosis

- 2001 Department of Family and Preventive Medicine, University of California San Diego, seminar:
Introduction to methods for decision analysis in health
- 2002 Dana Farber/ Harvard Cancer Center Outcomes Research Seminar:
Preferences for outcomes prevented by pneumococcal conjugate vaccine: challenges in using parents as proxies for valuing children's health states
- 2002 Department of Ambulatory Care and Prevention/Pharmaceutical Policy Research Seminar, Harvard Medical School:
Cost-effectiveness of cholesterol-lowering interventions: challenges of using CEA in decision-making
- 2003 Department of Ambulatory Care and Prevention, Harvard Medical School, seminar:
Economic analysis of strategies to reduce influenza morbidity in children
- 2004 Department of Ambulatory Care and Prevention, Harvard Medical School, seminar:
Are managed care decisions consistent with public preferences?
- 2005 Department of Ambulatory Care and Prevention, Harvard Medical School, seminar:
The economics of childhood vaccination
- 2006 Harvard Newborn Medicine Epidemiology and Clinical Medicine Conference, Beth Israel Deaconess Medical Center:
Economic values for newborn screening of metabolic disorders and related outcomes
- 2006 Dept. of Health Policy and Management, Harvard School of Public Health, seminar:
Should we vaccinate more children against influenza? Projected health benefits, risks, and cost-effectiveness
- 2006 Department of Ambulatory Care and Prevention, Harvard Medical School, seminar:
Expanded newborn screening: The effect of false positive test results on quality of life
- 2010 Child Health Evaluation and Research (CHEAR) Unit, General Pediatrics, University of Michigan, seminar
Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in children and adults
- 2010 School of Pharmacy, University of Michigan, seminar

- Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States
- 2010 Department of Pediatrics, University of Michigan, Grand Rounds
Cost-effectiveness and Child Health
- 2011 Child Health Evaluation and Research (CHEAR) Unit, General Pediatrics, University of Michigan, seminar
Comparative effectiveness and child health
- 2011 Department of Pediatrics, University of Michigan, Grand Rounds
Newborn screening: Cost-effectiveness and health policy
- 2011 Neonatology Research Conference, University of Michigan, seminar
Newborn screening: Cost-effectiveness and health policy
- 2013 Child Health Evaluation and Research (CHEAR) Unit, General Pediatrics, University of Michigan, seminar
Influenza vaccination post-2009; Projected health benefits, risks, and cost-effectiveness
- 2013 Child Health Evaluation and Research (CHEAR) Unit, General Pediatrics, University of Michigan, seminar
Using decision analysis to inform newborn screening policy
- 2014 Institute for Healthcare Policy and Innovation Methods Seminar, University of Michigan
Introduction to conjoint analysis and related methods
- 2014 Child Health Evaluation and Research (CHEAR) Unit, General Pediatrics, University of Michigan, seminar
Measuring the spillover effects of illness on parents, spouses, and children
- 2015 Department of Pediatrics Fellows Seminar, University of Michigan Medical School
Mentoring models for faculty success
- 2015 Injury Center, School of Public Health, University of Michigan, seminar
Economic evaluation and child health policy
- 2015 Mock Study Section Panelist, School of Public Health, University of Michigan, WIDTH Seminar
- 2016 Robert Wood Johnson Clinical Scholars Program, University of Michigan, seminar
Using decision analysis for newborn screening policy

- 2016 IHPI Methods Seminar, University of Michigan
Introduction to conjoint analysis
- 2017 Pediatrics Clinical Research Conference, University of Michigan, seminar
Consideration of economic endpoints for clinical (and observational) trials
- 2017 Woodson Scholars Seminar, Dept of Pediatrics, University of Michigan,
seminar
Consideration of economic endpoints for clinical (and observational) trials
- 2017 Center for Healthcare Engineering and Patient Safety, University of
Michigan, seminar
Using Decision Modeling to Inform Newborn Screening Policy Decisions
for Pompe Disease: A Case Study
- 2018 mHealthy Advisory Committee, University of Michigan, seminar
Vaccine decision making

Continuing Medical Education Courses

- 2003-2005 Lecturer and Core Course Faculty: Cost-effectiveness Analysis for
Medical Technologies and Pharmaceuticals (summer executive course),
Harvard School of Public Health
40 students, 6 hours
- 2012 Lead Instructor: Comparative Effectiveness, Decision Sciences, and Child
Health (3-hour workshop), Pediatric Academic Societies Annual Meeting
35 attendees, 12 hours
- 2013 Lead Instructor: Comparative Effectiveness, Decision Sciences, and Child
Health (3-hour workshop), Pediatric Academic Societies Annual Meeting
35 attendees, 12 hours
- 2014 Co- Instructor: Comparative Effectiveness, Decision Sciences, and Child
Health (3-hour workshop), Pediatric Academic Societies Annual Meeting
25 attendees, 12 hours

Dissertation Committees

- | | | |
|-----------|--------|---|
| 2002-2008 | Member | Eileen Sandberg, PhD, PhD Program in Health Policy, Harvard University |
| 2007-2010 | Member | April Kimmel, PhD, PhD Program in Health Policy, Harvard University |
| 2009-2012 | Chair | Davene Wright, PhD Program in Health Policy, Harvard University |

| | | |
|--------------|--------|---|
| 2009-2012 | Chair | Tara Lavelle, PhD Program in Health Policy, Harvard University |
| 2011-2012 | Member | Jongwha Chang, PhD, Social and Administrative Science, College of Pharmacy, University of Michigan |
| 2011-2013 | Member | Brian Davis, PhD Candidate, Department of Epidemiology, School of Public Health, University of Michigan |
| 2014-2017 | Chair | Michael Harvey, PhD Candidate, Health Services Organization and Policy, School of Public Health, University of Michigan |
| 2014-2017 | Chair | Anup Das, PhD Candidate, Health Services Organization and Policy (MD/PhD Program), School of Public Health, University of Michigan |
| 2016-2018 | Member | Michael Rozier, PhD Candidate, Health Services Organization and Policy (MD/PhD Program), School of Public Health, University of Michigan |
| 2016-2018 | Member | John Richardson, PhD Candidate, Health Services Organization and Policy (MD/PhD Program), School of Public Health, University of Michigan |
| 2017-present | Chair | Huey-Fen Chen, PhD Candidate, Health Services Organization and Policy (MD/PhD Program), School of Public Health, University of Michigan |

Committee, Organizational, and Volunteer Service

Institutional

| | |
|--------------|--|
| 2002-2006 | Member, Joint Committee on the Status of Women, Harvard Medical School Chair, Subcommittee on Faculty Parental Leave Policy (2002-2005) |
| 2006-2009 | Member, Committee on Higher Degrees in Health Policy, Harvard University |
| 2007 | Faculty Search Committee, Department of Ambulatory Care & Prevention, Harvard Medical School |
| 2007-2008 | Member, Evidence Review Group, Institute for Clinical and Economic Review, Massachusetts General Hospital |
| 2009-2010 | Member, Pediatric Psychosocial Services Committee, Department of Pediatrics, University of Michigan Health System |
| 2010-present | Member, ADVANCE Advisory Group, University of Michigan Medical School |

| | |
|--------------|--|
| 2010-present | Member, Faculty Development Advisory Committee, University of Michigan Medical School |
| 2011-present | Member, Mentor Committee, University of Michigan Medical School |
| 2012-present | Member, Health Services Organization and Policy Doctoral Program Committee, University of Michigan School of Public Health |
| 2012-2014 | Member, Research Advisory Committee, Department of Pediatrics and Communicable Diseases |
| 2014-2015 | Planning Committee Member, Faculty Development Symposium, University of Michigan Medical School |
| 2014-present | Member, Women in Academic Medicine Leadership Committee, University of Michigan Medical School |
| 2014-present | Member, Institute for Healthcare Policy and Innovation (IHPI) Education and Training Workgroup, University of Michigan |
| 2015-present | Member, Leadership Development Advisory Group, University of Michigan Medical School |
| 2015-present | Member, Advancing Women and Inclusive Leadership Subcommittee, University of Michigan Medical School |
| 2015-2016 | Member, Faculty Search Committee, School of Dentistry |
| 2016-present | Member, Institute for Healthcare Policy and Innovation (IHPI) Leadership Team, University of Michigan |
| 2016-present | Chair, Faculty Search Committee, Child Health Evaluation and Research Center |
| 2017 | ADVANCE University Advisory Committee, Office of the Provost |
| 2017-2018 | Parental Leave Advisory Committee, Office of the Provost |
| 2017-present | Member, Health System Science Curriculum Work Group, Medical School |
| 2018-present | Senior Faculty Advisor, IHPI Early Career Faculty Council |

Regional

| | |
|------|--|
| 2007 | Member, Research Grants Review Committee, State of Pennsylvania Department of Health |
|------|--|

National

- 2004 Special Reviewer, Research Grants Review Committee, National Eye Institute
- 2005 Co-Lead, Advisory Committee on Immunization Practices Influenza Working Group, Economic Subgroup to Review Economic Evidence for Prioritizing Target Groups in Vaccine Shortage Years, Centers for Disease Control and Prevention
- 2005 Member, New Vaccines for Adolescents: National Stakeholders Meeting, Centers for Disease Control and Prevention/National Vaccine Advisory Committee
- 2005-2009 Member, Database Advisory Panel, National Multiple Sclerosis Society
- 2005-2007 Lead Decision Scientist, Institute for Clinical and Economic Review, Harvard Medical School and Harvard Pilgrim Health Care
- 2006 Member, Peer Review Advisory Panel, Cost-effectiveness of Treatments in Multiple Sclerosis (COSTRIMS) Study
- 2006 Special Reviewer, Research Grants Review Committee, Decision, Risk and Management Sciences Program, National Science Foundation
- 2006 Participant, Modeling Review Committee, Project MOVE – Measurement of the Value of Exercise, Centers for Disease Control and Prevention
- 2006 Member, Fellowship Standards Task Force, International Society for Pharmacoeconomics and Outcomes Research
- 2007-present Member, Evidence Review Group, Advisory Committee on Heritable Disorders in Newborns and Children, Health Resources and Services Administration
- 2007 Special Reviewer, Canada Foundation for Innovation
- 2008 Lead, Advisory Committee on Immunization Practices Influenza Working Group, Economic Subgroup to Review Economic Evidence for Vaccinating Healthy Working-Age Adults, Centers for Disease Control and Prevention
- 2008 Reviewer, Special Emphasis Panel, Centers for Disease Control and Prevention

| | |
|--------------|--|
| 2009 | Reviewer, Special Emphasis Panel, Agency for Healthcare Research and Quality |
| 2009-2011 | Member, Evidence Review Group, Institute for Clinical and Economic Review |
| 2010 | Member, Objective Review Committee, Maternal and Child Health Bureau and Health Resources and Services Administration's Division of Independent Review |
| 2010-2013 | Trustee, Society for Medical Decision Making |
| 2010-2013 | Chair, Publications Committee, Society for Medical Decision Making |
| 2011-present | Member, Shingles Working Group, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention |
| 2011 | Member, Evidence Evaluation Methods Working Group, Advisory Committee on Heritable Disorders in Newborns and Children, Health Resources and Services Administration |
| 2012 | Reviewer, Special Emphasis Panel, National Institute of Child Health and Human Development |
| 2012 | Member, Expert Advisory Panel, Conditions Review Process, Advisory Committee on Heritable Disorders in Newborns and Children, Health Resources and Services Administration |
| 2012 | Panel Member, NIH Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus |
| 2013-2017 | Member, 2 nd Panel on Cost-effectiveness in Health and Medicine |
| 2015-2016 | Reviewer, Concordance Study Section, Agency for Healthcare Research and Quality |
| 2015-present | Member, Reviewer, Healthcare Effectiveness and Outcomes Research (HEOR) Study Section, Agency for Healthcare Research and Quality |
| 2015-present | Member, Cost Analysis Workgroup, The Advisory Committee on Heritable Disorders, Health Resources and Services Administration |
| 2016-present | Member, Child Health Interest Group Advisory Committee, AcademyHealth |
| 2018-present | Member, Research Insights Project Advisory Committee, AcademyHealth |

International

- 2010 Special Reviewer, European ERANET PRIOMEDCHILD Programme (administrated by the Dutch Organisation for Health Research and Development)
- 2011 Special Reviewer, Medical Research Council (MRC) Grants Pre Award Peer Review Process, United Kingdom (MRC is the UK equivalent of NIH)
- 2013 Expert Panel Member, Value of Vaccines Meeting, Organized by the GAVI Alliance, January 14-15, 2013, Menthon-St-Bernard, France
- 2015 Special Reviewer, SickKids Foundation New Investigator Program, Toronto, Canada

Consulting Positions

- 2008-2010 Visiting Scientist, United Biosource

Visiting Professorships, Seminars, and Extramural Invited Presentations

Visiting Professorships

- 2013 Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto & Child Health Evaluative Sciences (CHES), SickKids Hospital, Toronto, Canada
- 2014 Department of Health Policy and Management, Fay W. Boozman College of Public Health, University of Arkansas
- 2016 Center for Child Health, Behavior, and Development, Seattle Children's Hospital

Seminars and Extramural Invited Presentations

- 2007 Initiative on Medication Management, Policy Analysis, Research & Training (IMPART), Dalhousie University, Halifax, Nova Scotia, Canada
Introduction to Markov models

Extramural Invited Presentations

- 2000 Annual Meeting of the Society for Medical Decision Making

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in multiple sclerosis

- 2001 Annual Meeting of the Society for Medical Decision Making
Do risk attitudes differ across domains and respondent types?
- 2003 Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention: Economic analysis of strategies to reduce influenza morbidity in children (presentation)
- 2003 National Immunization Program, Centers for Disease Control and Prevention: Economic analysis of strategies to reduce influenza morbidity in children (research seminar)
- 2004 Ninth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
An economic analysis of rapid tests and antiviral treatments for influenza in children (podium presentation)
- 2005 Tenth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Costs of delivering adult influenza vaccination in non-traditional settings (podium presentation)
- 2005 Advisory Committee on Immunization Practices Influenza Working Group Using economic information to prioritize subgroups during influenza vaccine shortages (presentation)
- 2006 Annual Meeting of the New England Consortium of Metabolic Programs
Cost-effectiveness of expanded newborn screening (presentation)
- 2007 12th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations (podium presentation)
- 2007 Center for Health Services Research, Henry Ford Health System
Projected costs, risks, and benefits of influenza vaccination of children (research seminar)
- 2007 Conference on Routine Vaccination Against Influenza for Older Children, Centers for Disease Control and Prevention
Projected health benefits, risks, and cost-effectiveness of influenza vaccination: Children aged 5-17 years (presentation)
- 2007 Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention

- Cost-effectiveness of influenza vaccination: updated estimates for children aged 2-4 years (presentation)
- 2008 Child Health Evaluation and Research (CHEAR) Unit, Department of Pediatrics, University of Michigan Medical School
Projected health benefits, risks, and cost-effectiveness of influenza vaccination (research seminar)
- 2008 Annual Conference on Vaccine Research, National Foundation for Infectious Diseases
Cost-effectiveness of universal vaccination, Symposium: Universal Vaccination Against Influenza (symposium speaker)
- 2008 30th Annual Meeting of the Society for Medical Decision Making
Valuing health across the lifespan (podium presentation)
- 2009 2009 Pediatric Academic Societies' Annual Meeting
Valuing health for children and adults (platform presentation)
- 2009 14th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research Eliciting time trade-off amounts for health states in hypothetical individuals of different ages using a discrete choice experiment (podium presentation)
- 2009 Centers for Disease Control and Prevention
Cost-effectiveness of pH1N1 influenza vaccination in the United States (research seminar)
- 2010 3rd Biennial Meeting of the American Society of Health Economists
Eliciting time trade-off amounts using a discrete choice experiment (organized session)
- 2010 3rd Biennial Meeting of the American Society of Health Economists
Use of proxies for valuing children's health (organized session)
- 2010 32nd Annual Meeting of Society of Medical Decision Making
Trends in utility elicitation methods: is there still a role for direct elicitation? (podium presentation)
- 2011 Eastern Economic Association Conference
Finding Utility Measures for Influenza Illness (organized session)
- 2011 Symposium – Global Vaccines 202x: Access, Equity, Ethics
Cost-effectiveness and vaccine policy (invited presentation)
- 2011 Centers for Disease Control and Prevention

- Community-based value for H1N1 influenza illnesses and vaccination-related adverse events (invited seminar)
- 2011 25th Meeting of the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children
Evidence evaluation and methods workgroup: Update on developing a decision analysis tree (invited presentation)
- 2011 Clinical Vaccinology Course sponsored by the National Foundation for Infectious Diseases and The Emory Department of Medicine
Cost-effectiveness of influenza vaccination (invited presentation)
- 2012 Clinical Vaccinology Course sponsored by the National Foundation for Infectious Diseases and The Emory Department of Medicine
Cost-effectiveness of influenza vaccination (invited presentation)
- 2012 National Influenza Vaccine Summit
Co-Sponsored by the CDC and the AMA
Cost-effectiveness of influenza vaccine (invited presentation)
- 2012 34th Annual Meeting of Society of Medical Decision Making Measuring family HRQOL spillover effects using direct health utility assessment. (podium presentation)
- 2013 Clinical Vaccinology Course sponsored by the National Foundation for Infectious Diseases and the Emory Department of Medicine
Cost-effectiveness of influenza vaccine (invited presentation)
- 2013 Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto
Comparative effectiveness & child health (seminar speaker)
- 2014 Seminar Series on Evidence-Based Medicine, University of Arkansas
Comparative effectiveness & child health (seminar speaker)
- 2014 Advisory Committee on Immunization Practices
Economic evaluation methods (workshop for ACIP members)
- 2014 Pediatric Academic Societies
Session: Advocacy for Child Health Research: the APS-COPR Success Story Project
Economic impacts of child health research (invited speaker)
- 2014 36th Annual Meeting of the Society for Medical Decision Making
Symposium: What Should the Role of CEA Be in Health Policy and Medical Decision Making
Cost-effectiveness Analysis and US Health Policy (invited speaker)

- 2015 Advisory Committee on Immunization Practices
Economic evaluation and measuring quality-adjusted life years (workshop for ACIP members)
- 2015 International Health Economics Association Annual Meeting
2nd Panel on Cost-Effectiveness in Health and Medicine: Motives, Methods, and Key Issues (invited speaker)
- 2015 International Health Economics Association Annual Meeting
Measuring Family HRQOL Spillover Effects for Newborn Screening & Conditions (invited speaker)
- 2015 Discretionary Advisory Committee for Heritable Disorders in Newborns and Children
Newborn Screening for X-linked Adrenoleukodystrophy (X-ALD): Final Report from the Condition Review Workgroup (invited speaker)
- 2015 Michigan Department of Health and Human Services
Newborn Screening Decisions: The Role of Cost-Effectiveness Evidence (invited speaker)
- 2015 Council for the Advancement of Nursing Science Annual Meeting
Innovative Methods to Accelerate Family Nursing Research (invited speaker)
- 2015 Agency for Healthcare Research and Quality Annual Conference
Methods for Measuring How Childhood Illness Affects Parents and Family Members (invited speaker)
- 2016 Newborn Screening for Neuromuscular Diseases International Meeting
Economic evaluation, newborn screening, and Pompe Disease
- 2016 Children's Vision: A National Workshop
Using Decision Analysis to Inform Newborn Screening Policy
- 2016 38th Annual Meeting of the Society for Medical Decision Making
Panel: Recommendations of the Second Panel on Cost-effectiveness in Health and Medicine (invited speaker)
- 2016 38th Annual Meeting of the Society for Medical Decision Making
Measuring Patient Preferences for Bariatric Surgery: A Discrete Choice Experiment (podium presentation)
- 2016 Seminar Series, Center for Child Health Behavior and Development, Seattle Children's Hospital
Family effects of illness (seminar speaker)

- 2016 Conference: Second Panel on Cost-Effectiveness in Health and Medicine, National Academy of Sciences
Reporting results of cost-effectiveness analyses (invited speaker)
- 2016 Center for Child Health, Behavior, and Development, Seattle Children's Hospital, seminar
Family effects of illness (invited speaker)
- 2017 Grand Rounds, Helen DeVos Children's Hospital
Using decision analysis to inform newborn screening policy (invited speaker)
- 2017 Second Panel on Cost-Effectiveness in Health and Medicine, International Health Economics Association Annual Meeting, Boston, MA, 2017
Reporting results of cost-effectiveness analyses (invited speaker)
- 2017 Orphan Drug Assessment and Pricing Summit, Institute for Clinical and Economic Review, Washington, DC
Price, Cost-effectiveness, and Affordability (invited panel member)
- 2017 Center for Health Decision Science, Harvard T.H. Chan School of Public Health, seminar
Economic evaluation of vaccination for prevention of herpes zoster and related complications
- 2017 Advisory Committee on Immunization Practices
Economic evaluation of vaccination for prevention of herpes zoster and related complications
- 2018 Advisory Committee for Heritable Disorders in Newborns and Children
Population-level outcomes for newborn screening of spinal muscular atrophy

Bibliography

Peer-reviewed Publications

1. **Prosser LA**, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. *Am J Manag Care*. 2000;6(2):173-179.
2. **Prosser LA**, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. *Ann Intern Med*. 2000;132(10):768-779.

3. **Prosser LA**, Stinnett AA, Goldman L, Weinstein MC. Cost-effectiveness analyses (letter). *Ann Intern Med.* 2001;135(5):383.
4. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. *Med Decis Making.* 2002;22:506-513.
5. Lieu TA, Thompson KM, **Prosser LA**, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. *Expert Rev Vaccines.* 2002;1(4):433-442.
6. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. *Mult Scler.* 2003;9:311-319.
7. Wang SJ, Middleton B, **Prosser LA**, Bardon CG, Spurr CD, Carchidi PJ, Kittler AF, Goldszer RC, Fairchild DG, Sussman AJ, Kuperman GJ, Bates DW. A cost-benefit analysis of electronic medical records in primary care. *Am J Med.* 2003;114(5):397-403.
8. **Prosser LA**, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. *Pediatrics.* 2004;113(2):283-290.
9. **Prosser LA**, Lieu TA. Comments on the Prosser et al approach to value disease reduction in children: In reply (letter). *Pediatrics.* 2004;114:1375-1376.
10. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. *Value Health.* 2004;7(5):554-568.
11. **Prosser LA**, Bridges CB, Uyeki TM, Rego VH, Ray GT, Meltzer MI, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Values for preventing influenza-related morbidity and vaccine adverse events in children. *Health Qual Life Outcomes.* 2005;3(18):1-16.
12. Simon SR, Majumdar SR, **Prosser LA**, Salem-Schatz S, Warner C, Kleinman K, Miroshnik I, Soumerai SB. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. *Am J Med.* 2005;118(5):521-528.
13. Gupta RS, Bewtra M, **Prosser LA**, Finkelstein JA. Predictors of hospital charges for children admitted with asthma. *Ambul Pediatr.* 2006;6(1):15-20.
14. Wittenberg E, Halpern E, Divi N, **Prosser LA**, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. *Qual Life Res.* 2006;15(4):645-653.
15. Skelding PC, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, **Prosser L**, Simon SR. Clinical and non-clinical correlates of adherence to prescribing

guidelines for hypertension in a large managed care organization. *J Clin Hypertension*. 2006;8(6):414-419.

16. **Prosser LA**, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. *Emerg Infect Dis*. 2006;12(10):1548-1558.
17. Eisenberg DM, Post DE, Davis RB, Connelly MT, Legedza AT, Hrbek AL, **Prosser LA**, Buring JE, Cherkin DC. Addition of choice of complementary therapies to usual care for acute low back pain: a randomized controlled trial. *Spine*. 2007;32(2):151-8.
18. **Prosser LA**, Corso PS. Measuring health-related quality of life for child maltreatment: a systematic literature review. *Health Qual Life Outcomes*. 2007;5:11-17.
19. Simon SR, Rodriguez HP, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Soumerai SB, **Prosser LA**. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications. *J Clin Hyper*. 2007;9(1):15-20.
20. **Prosser LA**, Wittenberg E. Do risk attitudes differ across domains and respondent types? *Med Decis Making*. 2007;27(3):281-287.
21. **Prosser LA**, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: theoretical and methodological considerations. *PharmacoEconomics*. 2007;25(9):713-726.
22. Ladapo JA, Neumann PJ, Keren R, **Prosser LA**. Valuing children's health: a comparison of cost-utility analyses for adult and pediatric health interventions (review). *PharmacoEconomics*. 2007;25(10):817-828.
23. **Prosser LA**, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Wortley PM, Messonnier ML, Lieu TA. Non-traditional settings for influenza vaccination of adults: costs and cost-effectiveness. *PharmacoEconomics*. 2008;26(2):163-178.
24. Ortega-Sanchez IR, Lee GM, Jacobs RJ, **Prosser LA**, Molinari NA, Zhang X, Baine WB, McCauley MM, Miller T. Projected cost-effectiveness of new vaccines for adolescents in the United States (review). *Pediatrics*. 2008;121. Suppl 1:S63-78.
25. Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, **Prosser LA**. Community and patient values for preventing zoster. *PharmacoEconomics*. 2008;26(3):235-249.
26. **Prosser LA**, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance for false-positive newborn screening results. *Arch Pediatr Adolesc Med*. 2008;162(9):870-876.

27. O'Brien MA, **Prosser LA**, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen V, Mehta J, Colborne JK, Lieu TA. New vaccines against otitis media: projected benefits and cost-effectiveness. *Pediatrics*. 2009;123(6):1452-1463.
28. **Prosser LA**. Current challenges and future research in measuring preferences for pediatric health outcomes (invited editorial). *J Pediatr*. 2009;155(1):7-9.
29. Wright DR, Wittenberg E, Swan JS, Miksad RA, **Prosser LA**. Methods for measuring temporary health states for cost-utility analyses (review). *Pharmacoeconomics*. 2009;27(9):713-723.
30. Lipstein EA, Perrin JM, Waisbren SE, **Prosser LA**. Impact of false-positive newborn metabolic screening results on early health care utilization. *Genet Med*. 2009;11(10):1-6.
31. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, **Prosser LA**. Willingness-to-pay for a quality-adjusted life-year based on community member and patient preferences for temporary health states associated with zoster. *Pharmacoeconomics*. 2009;27(12):1005-1016.
32. Sonnevile KR, La Pelle N, Taveras EM, Gillman MW, **Prosser LA**. Economic and other barriers to adopting recommendations to prevent childhood obesity: results of a focus group study with parents. *BMC Pediatrics*. 2009;9(81):1-21.
33. **Prosser LA**, Kong CY, Rusinak D, Waisbren SE. Projected costs, risks, and benefits of expanded newborn screening for MCADD. *Pediatrics*. 2010;125(2):e286-294.
34. Lipstein EA, Vorono S, Browning MF, Green NS, Kemper AR, Knapp AA, **Prosser LA**, Perrin JM. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. *Pediatrics*. 2010;125(5):e1226-1235.
35. McBrien K, Abrams A, Kleinman K, **Prosser LA**. Use of outcomes-weighted ROC curves to evaluate surveillance systems for bioterrorist attacks. *BMC Med Inform Decis Making*. 2010;10:1-11.
36. Grosse SD, **Prosser LA**, Asakawa K, Feeny D. QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique. *Expert Rev Pharmacoecon Outcomes Res*. 2010;10(3):293-308.
37. Perrin JM, Knapp AA, Browning MF, Comeau AM, Green NS, Lipstein EA, Metterville DR, **Prosser L**, Queally D, Kemper AR. An evidence development process for newborn screening. *Genet Med*. 2010;12(3):131-134.
38. **Prosser LA**, Payne K, Rusinak D, Shi P, Uyeki T, Messonnier M. Valuing health across the lifespan: health state preferences for seasonal influenza illnesses in patients of different ages. *Value Health*. 2011;14(1):135-143.

39. Wang YC, Cheung AM, Bibbins-Domingo K, **Prosser LA**, Cook NR, Goldman L, Gillman MW. Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States. *J Pediatr*. 2011;158(2):257-264.
40. Belfort M, Zupancic J, Riera K, Turner J, **Prosser LA**. Health state preferences associated with weight status in children and adolescents. *BMC Pediatrics*. 2011;11(1):12.
41. **Prosser LA**, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, Lieu TA. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. *Arch Pediatr Adolesc Med*. 2011;165(2):112-118.
42. Bridges JFP, Hauber AB, Marshall D, Lloyd A, **Prosser LA**, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. *Value Health*. 2011;14(4):403-413.
43. Eisenberg D, Freed GL, Davis MM, Singer D, **Prosser LA**. Valuing health at different ages: evidence from a nationally representative survey in the United States. *Appl Health Econ Health Policy*. 2011;9(3):149-156.
44. Wittenberg E, **Prosser LA**. Ordering errors, objections and invariance in utility survey responses: a framework for understanding who, why and what to do. *Appl Health Econ Health Policy*. 2011;9(4):225-241.
45. Taveras EM, Gortmaker SL, Hohman KH, Horan CM, Kleinman KP, Mitchell K, Price S, **Prosser LA**, Rifas-Shiman SL, Gillman MW. A randomized controlled trial to improve primary care to prevent and manage childhood obesity: the High Five for Kids study. *Arch Pediatr Adolesc Med*. 2011;165(8):714-22.
46. Rhodes ET, **Prosser LA**, Lieu TA, Songer TJ, Ludwig DS, Laffel LM. Preferences for type 2 diabetes health states among adolescents with or at risk of type 2 diabetes mellitus. *Pediatric Diabetes*. 2011;12(8):724-32.
47. **Prosser LA**, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. *PLoS ONE*. 2011;6(7):e22308.
48. Lavelle TA, Meltzer MI, Gebremariam A, Lamarand K, Fiore AE, **Prosser LA**. Community-based values for 2009 pandemic influenza A(H1N1) illnesses and vaccination-related adverse events. *PLoS ONE*. 2011;6(12):e27777.
49. Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, **Prosser LA**. Seasonal influenza vaccination of healthy, working-age adults: a review of economic evaluations. *Drugs*. 2012;72(1):35-48

50. Lavelle TA, Uyeki TM, **Prosser LA**. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza. *J Pediatr*. 2012;160(1):67-73.
51. **Prosser LA**, Grosse SD, Wittenberg E. Health utility elicitation. Is there still a role for direct methods? *PharmacoEconomics*. 2012; 30(2):1-4.
52. Rhodes ET, **Prosser LA**, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. *Diab Med*. 2012;29(4):453-63.
53. Kimmel AD, Daniels N, Betancourt TS, Wood R, **Prosser LA**. Decision maker priorities for providing antiretroviral therapy in HIV-infected South Africans: a qualitative assessment. *AIDS Care*. 2012;24(6):778-92.
54. Rhodes ET, Goran MI, Lieu TA, Lustig RH, **Prosser LA**, Songer TJ, Weigensberg MJ, Weinstock RS, Gonzalez T, Rawluk K, Zoghbi RM, Ludwig DS, Laffel LM. Health-related quality of life in adolescents with or at risk for type 2 diabetes mellitus. *J Pediatr*. 2012;160(6):911-7.
55. Dempsey AF, Pangborn HM, **Prosser LA**. Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus vaccine. *Vaccine*. 2012;30(27):4060-6.
56. Gidengil C, Lieu TA, Payne K, Rusinak D, Messonnier M, **Prosser LA**. Parental and societal values for the risks and benefits of childhood combination vaccines. *Vaccine*. 2012;30(23):3445-52.
57. **Prosser LA**, Grosse SD, Kemper AR, Tarini BA, Perrin JM. Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. *Genet Med*. 2012;14(8):703-712.
58. **Prosser LA**. Comparative effectiveness and child health. *PharmacoEconomics*. 2012; 30(8):637-45.
59. Song JW, Chung KC, **Prosser LA**. Treatment of ulnar neuropathy at the elbow: cost-utility analysis. *J Hand Surg*. 2012;37(8):1617-1629.e3.
60. Chang J, Freed G, **Prosser LA**, Patel I, Erickson S, Bagozzi R, Balkrishnan R. Associations between physician financial incentives and prescribing of anti-asthmatic medications in children in US outpatient settings. *Journal of Child Health*. 2013;17(2):125-137.
61. Wittenberg E, Ritter G, **Prosser LA**. Evidence of spillover of illness among household members: EQ-5D scores from a US sample. *Med Decis Making*. 2013;33(2):235-243.
62. **Prosser LA**, Payne K, Rusinak D, Shi P, Messonnier M. Using a discrete choice experiment to elicit time trade-off and willingness-to-pay amounts for influenza health-related quality of life at different ages. *PharmacoEconomics*. 2013;31(4):305-315.

63. Chang J, Freed G, **Prosser LA**, Patel I, Erikson S, Bagozzi R, Balkrishnan R. Comparisons of health care utilization outcomes in children with asthma enrolled in private insurance plans versus Medicaid. *J Pediatr Health Care*. 2014;28(1):71-79.
64. Wittenberg E, Saada A, **Prosser LA**. How illness affects family members: a qualitative interview survey. *The Patient*. 2013;6(4):257-268.
65. Ungar WJ, **Prosser LA**, Burnett HF. Values and evidence colliding: health technology assessment in child health. *Expert Rev Pharmacoecon Outcomes Res*. 2013;13(4):417-419.
66. Kemper A, Green N, Calonge N, Lam W, Comeau A, GoldenbergA, Ojodu J, **Prosser LA**, Tanksley S and Bocchini Jr, J. Decision-making process for conditions nominated to the Recommended Uniform Screening Panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on heritable disorders in newborns and children. *Genet Med*. 2014;16(2):183-187.
67. Zickafoose JS, DeCamp LR, **Prosser LA**. Association between enhanced access services in pediatric primary care and utilization of emergency departments: a national parent survey. *J Pediatr*. 2013. 163(5):1389-1395 e1381-1386.
68. Vandorsten J, Dodson W, Espeland M, Grobman W, Guise J, Mercer B, Minkoff H, Poindexter B, **Prosser LA**, Sawaya G, Scott J, Silver R, Smith L, Thomas A, Tita A. NIH consensus development conference: diagnosing gestational diabetes mellitus. *NIH consensus and state-of-the-science statements*. 2013;29(1):1-31.
69. Wittenberg E, **Prosser LA**. Disutility of illness for caregivers and families: a systematic review of the literature. *Pharmacoeconomics*. 2013;31(6):489-500.
70. Zickafoose JS, DeCamp LR, Sambuco DJ, **Prosser LA**. Parents' preferences for enhanced access to the pediatric medical home: a qualitative study. *J Amb Care Mgmt*. 2013;36(1):2-12.
71. Sharp A, **Prosser LA**, Walton M, Blow F, Chermack S, Zimmerman M, Cunningham R. Cost analysis of youth violence prevention. *Pediatrics*. 2014;133(3):448-453.
72. Lavelle T, Weinstein M, Newhouse J, Munir K, Kuhlthau K, **Prosser LA**. Economic burden of childhood autism spectrum disorders. *J Pediatr*. 2014; 133(3);e520-9.
73. Sears ED, Shin R, **Prosser LA**, Chung KC. Economic analysis of revision amputation and replantation treatment of finger amputation injuries. *Plast Reconstr Surg*. 2014;133(4):827-840.
74. Lavelle T, Wittenberg E, Lamarand K, **Prosser LA**. Variation in the spillover effects of illness on parents, spouses and children of the chronically ill. *Appl Health Econ Health Policy*. 2014;12(2):117-124.

75. Wright D, Taveras E, Gillman M, Horan C, Hohman K, Gortmaker S, **Prosser LA**. The cost of a primary care-based childhood obesity prevention intervention. *BMC Health Services Research*. 2014;14:44.
76. Wright D, **Prosser LA**. The impact of overweight and obesity on pediatric medical expenditures. *Appl Health Econ Health Policy*. 2014;12(2):139-150.
77. Bärnighausen T, Berkley S, Bhutta Z, Bishai D, Black M, Bloom D, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani F, Hutubessy R, Jamison D, Jha P, Jit M, Johnson H, Laxminarayan R, Lee B, Mhatre S, Mills A, Nordström A, Ozawa S, **Prosser L**, Silver K, Stabell Benn K, Standaert B, Walker D. Reassessing the value of vaccines. *Lancet Glob Health*. 2014;2(5):e251-e252.
78. **Prosser LA**, Lamarand K, Gebremariam A, Wittenberg E. Measuring family HRQOL spillover effects using direct health utility assessment methods. *Med Decis Making*. 2015;35(1):81-93.
79. Lipstein EA, Brinkman WB, Hendrix KS, Kryworuchko J, Miller VA, **Prosser LA**, Ungar W, Fox D. An emerging field of research: Challenges in pediatric decision making. *Med Decis Making*. 2015;35(3):403-408.
80. Zickafoose JS, DeCamp LR, **Prosser LA**. Parents' preferences for enhanced access in the pediatric medical home: a discrete choice experiment. *JAMA Pediatrics*. 2015; 169(4):358-364.
81. Harvey MJ, Gaies MG, **Prosser LA**. US and international in-hospital costs of extracorporeal membrane oxygenation: a systematic review. *Appl Health Econ Health Policy*. 2015;13(4):341-357.
82. Nelson C, Kokorowski P, Routh J, Logvinenko T, Rosoklija I, **Prosser LA**, Schuster M. Utility scores for vesicoureteral reflux and anti-reflux surgery. *J Peds Urology*. 2015;11(4):177-182.
83. Kemper AR, **Prosser LA**, Wade KC, Repka MX, Ying G, Baumritter A, Quinn GE. A comparison of strategies for retinopathy of prematurity detection. *Pediatrics*. 2016;137(1):1-10.
84. Goldenberg AJ, Comeau AM, Grosse SD, Tanksley S, **Prosser LA**, Ojodu J, Botkin JR, Kemper AR, Green NS. Evaluating harms in the assessment of net benefit: A framework for newborn screening condition review. *Matern Child Hlth J*. 2016;20(3):693-700.
85. **Prosser LA**. Statistical methods for the analysis of discrete-choice experiments: A report of the ISPOR Conjoint Analysis Good Research Practices Task Force (editorial). *Value Health*. 2016;19(4):298-9.
86. Wittenberg E, **Prosser LA**. Health as a Family Affair. *New Engl J Med*. 2016;374(19):1804-1806.

87. Rifas-Shiman SL, Taveras EM, Gortmaker SL, Hohman KH, Horan CM, Kleinman KP, Mitchell K, Price S, **Prosser LA**, Gillman MW. Two year follow-up of a primary care-based intervention to prevent and manage childhood obesity: The High Five for Kids Study. *Pediatric Obesity*. 2016; in press.
88. Harvey MJ, **Prosser LA**, Messonnier M, Hutton DW. Hitting the optimal vaccination percentage and the risks of error: Why to miss right. *PLoS ONE*. 2016; 11(6):e0156737.
89. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, **Prosser LA**, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *JAMA*. 2016;316(10):1093-1103.
90. Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E, Kwon JM, Lam WK, Ojuda J, Prosser LA, Tanksley S. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. *Genet Med*. 2017; 19(1):121-126.
91. Barbaro RP, Boonstra PS, Moler FW, Davis MM, **Prosser LA**. Hospital-level variation in inpatient cost among children receiving extracorporeal membrane oxygenation. *Perfusion*. 2017; 32(17):538-546.
92. McGrady ME, **Prosser LA**, Thompson AN, Pai ALH. Application of a discrete choice experiment to assess adherence-related motivation among adolescents and young adults with cancer. *J Pediatr Psychol*. 2017; [Epub ahead of print].
93. Gauger TL, **Prosser LA**, Fontana M, Polverini PJ. Integrative and collaborative care models between pediatric oral health and primary care providers: A review of the literature. *J Public Health Dentistry*. In press.
94. **Prosser LA**, Lam KK, Grosse SD, Casale M, Kemper AR. Using decision analysis to support newborn screening policy decisions: A case study for Pompe disease. *MDM Policy & Practice*. 2018. In press.
95. Harvey MJ, Denton BT, **Prosser LA**, Hutton DW. Determining the optimal strategy for the herpes zoster vaccine. *Vaccine*. In press.
96. Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, **Prosser LA**, Lachin JM. What are the Clinical, Quality-of-Life, and Cost Consequences of 30 Years of Excellent vs. Poor Glycemic Control in Type 1 Diabetes? *Journal of Diabetes and its Complications*. In press.
97. Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, **Prosser LA**, Lachin JM. The 30-Year Cost-Effectiveness of Alternative Strategies to Achieve Excellent Glycemic Control in Type 1 Diabetes: An Economic Simulation Informed by

the Results of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). *Journal of Diabetes and its Complications*. In press.

98. Tarini B, Simon N, Payne K, Gebremariam A, Rose A, **Prosser LA**. An assessment of public preferences for newborn screening using best-worst scaling. *Journal of Pediatrics*. In press.
99. Sun X, Huang Z, Wagner AL, **Prosser LA**, Xu E, Ren J, Wang B, Yan W, Zikmund-Fisher BJ. Parent and caregiver perceptions and beliefs in natural infections in Shanghai parents' vaccine decision-making: a qualitative study. *BMC Public Health*. 2018;18(1):813.
100. Huang Z, Sun X, Wagner AL, Ren J, Boulton ML, **Prosser LA**, Zikmund-Fisher BJ. Parent and caregiver perceptions about the safety and effectiveness of foreign and domestic vaccines in Shanghai, China. *PLoS One*. 2018; 13(5):e0197437.

Reports (Non-Peer Reviewed)

1. Pearson SD, Ladapo J, **Prosser LA**. Intensity modulated radiation therapy (IMRT) for localized prostate cancer. Final appraisal document. Institute for Clinical and Economic Review. November, 2007. Available at: <http://www.icer-review.org/index.php/imrt.html>.
2. Evidence Review: Pompe Disease. Prepared for: Maternal and Child Health Bureau. 2008. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-evidence-review-report-2008.pdf>.
3. Evidence Review: Krabbe Disease. Prepared for: Maternal and Child Health Bureau. 2009. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/krabbe-disease-evidence-review-report.pdf>.
4. Evidence Review: Severe Combined Immunodeficiency (SCID). Prepared for: Maternal and Child Health Bureau. 2009. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/scid-external-evidence-review-report.pdf>.
5. Evidence Review: Critical Congenital Cyanotic Heart Disease (CCCHD). Prepared for: Maternal and Child Health Bureau. 2010. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/cyanotic-heart-external-evidence-review-report.pdf>.
6. Evidence Review: Neonatal Hyperbilirubinemia. Prepared for: Maternal and Child Health Bureau. 2012. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/hyperbilirubinemia-evidence-review-report.pdf>.
7. Evidence Report: Newborn Screening for Pompe Disease. Prepared for: Maternal and Child Health Bureau. 2013. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/pompe-external-evidence-review-report-2013.pdf>.

8. Newborn Screening for Mucopolysaccharidosis Type 1 (MPS I): A Systematic Review of Evidence. Prepared for: Maternal and Child Health Bureau. 2015. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/mps1-external-evidence-review-report.pdf>.
9. Newborn Screening for X-Linked Adrenoleukodystrophy (X-ALD): A Systematic Review of Evidence. Prepared for: Maternal and Child Health Bureau. 2017. Available at: <https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/previous-nominations/xald-external-evidence-review-report.pdf>.

Book Chapters

1. **Prosser LA**, Payne K. Discrete Choice. Encyclopedia of Medical Decision Making. Thousand Oaks, CA: SAGE Publications. 2009.
2. Neumann PJ, Russell LB, Siegel JE, **Prosser LA**, Krahn M, Mandelblatt JS, Daniels N, Gold MR. Chapter 1: Using Cost-Effectiveness in Health and Medicine. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. *Cost-Effectiveness in Health and Medicine*, 2nd edition. Editors: New York: Oxford University Press, 2017: 1-38.
3. Feeny D, Krahn M, **Prosser LA**, Salomon JA. Chapter 7: Valuing Health Outcomes. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. *Cost-Effectiveness in Health and Medicine*, 2nd edition. Editors: New York: Oxford University Press, 2017: 167-200.
4. **Prosser LA**, Neumann PJ, Sanders GD, Siegel JE. Chapter 13: Reporting Cost-Effectiveness Analyses. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. *Cost-Effectiveness in Health and Medicine*, 2nd edition. Editors: New York: Oxford University Press, 2017: 343-368.

Theses

1. **Prosser LA**. Pharmaceutical research and development: the effects of increased competition on human resource strategies [master's thesis]. Boston (MA): MIT; 1992.
2. **Prosser LA**. Patient preferences and economic considerations in treatment decisions for multiple sclerosis [dissertation]. Cambridge (MA): Harvard University; 2000.

Other Media

1. Prosser L. "Why Some Forgo the Flu Shot". National Public Radio. 11/27/06.
2. Prosser L. Screening for MCADD Outweighs Risks. UPI.com. 02/03/2010
3. Prosser L, Kong CY, Rusinak D, Waisbren SL. Benefits Outweigh Risks Associated with Newborn Screening for Disorder. Science Daily. 02/11/2010
4. Prosser L. Newborn Screening. Public Health Minute. 10/28/2015.

5. New set of recommendations developed to improve quality of cost-effectiveness analyses. Science Daily. 09/13/2016.

Abstracts

(This section includes only presented abstracts not yet published as peer-reviewed journal articles.)

1. **Prosser LA**, Concannon TW, Pearson SD, Hammitt JK. An internet survey of public preferences for characteristics of health interventions. *Med Decis Making*. 2005;25(1):E57.
2. **Prosser LA**, Griffin M, Keren R, Meltzer MI, Ortega-Sanchez I, Herrera G, Messonnier ML, Bridges CB. Using economic evidence to prioritize subgroups during an influenza vaccine shortage. *Med Decis Making*. 2006;26(1):E77.
3. **Prosser LA**, Wittenberg E. Valuing children's health: response issues with using parents as proxies. *Med Decis Making* 2007;25(1):E57.
4. Sandberg EA, **Prosser LA**, Neumann P, Weinstein MC. Health state utilities in children ages 7-10 with attention deficit hyperactivity disorder. *Med Decis Making*. 2008;25(1):E72.
5. Sandberg EA, Thompson K, **Prosser LA**, Neumann P, Weinstein MC. The cost-effectiveness of treatments for attention deficit hyperactivity disorder (ADHD) in children ages 7-10. Presented at the 30th Annual Meeting of the Society for Medical Decision Making, October 21, 2008, Philadelphia, PA.
6. Srivastava R, Barnhart DC, Campbell K, Mahant S, Goldin AB, Mundorff M, Dasgupta R, Dean JM, **Prosser LA**. Fundoplication Versus Gastrojejunal Feeding Tubes To Treat Gastroesophageal Reflux Disease in Children with Neurological Impairment: A Markov Model. Presented at the Pediatric Academic Societies' Annual Meeting, May 5, 2009, Baltimore, MD.
7. Van Mater HA, Davis MM, **Prosser LA**. Treatment of refractory Kawasaki Disease: Cost-effectiveness analysis of infliximab versus IVIG. Presented at the Pediatric Academic Societies' Annual Meeting, May 1, 2010, Vancouver, BC, Canada.
8. **Prosser L**. Use of proxies for valuing children's health: potential biases and recommended approaches. Presented at the 3rd Biennial Conference of the American Society of Health Economists; June 20-23, 2010. Ithaca, NY.
9. Wright DR, Taveras E, Gillman M, Horan CM, Hohman KH, Gortmaker S, **Prosser L**. The cost effectiveness of High Five for Kids: A pediatric primary care obesity prevention program. *Med Decis Making*. 2011;31:E77.

10. Lee J, Gebremariam A, Davis MM, **Prosser L**, Vijan S. The impact of increasing degree and duration of obesity among US birth cohorts on Type 2 Diabetes trends in the US. *Med Decis Making*. 2011;31:E161.
11. Wright DR, **Prosser L**. Estimating medical expenditures for childhood obesity cost-effectiveness analysis. Presented at the 33rd Annual Meeting of the Society for Medical Decision Making, October 24, 2011, Chicago, IL.
12. Lavelle T, Weinstein M, Newhouse J, Kuhlthau K, Munir K, **Prosser L**. Parent and Child Health Utilities Associated with Autism Spectrum Disorders. Presented at the 34th Annual Meeting of the Society for Medical Decision Making, October 17-20, 2012, Phoenix, AZ
13. Wright D, Kim J, **Prosser L**. Simulating Collateral Weight Loss Within Social Networks: Capitalizing on Spillover Effects to Improve Health. Presented at the 34th Annual Meeting of the Society for Medical Decision Making, October 17-20, 2012, Phoenix, AZ
14. **Prosser LA**, Grosse SD, Casale MT, Lam KK, Kemper A. Population Level Outcomes for Newborn Screening for Pompe Disease Compared with Clinical Identification. Presented at the Pediatric Academic Societies Annual Meeting, April 29 - May 3, 2016, Baltimore, MD.
15. Tarini B, Gebremariam A, Simon N, **Prosser LA**. Using Best-worst Scaling to Measure Public Values for Newborn. Presented at the Pediatric Academic Societies Annual Meeting, April 29 - May 3, 2016, Baltimore, MD.
16. Hutton DW, **Prosser LA**. Cost-effectiveness of Expanded Adolescent HPV Vaccine Coverage. Presented at the 38th Annual Meeting of the Society for Medical Decision Making, October 23-26, 2016, Vancouver, Canada.
17. **Prosser LA**, Birkmeyer N, Simon NJ, Rozier M, Hawley S, Ghaferi A. Measuring Patient Preferences for Bariatric Surgery: A Discrete Choice Experiment. Presented at the 38th Annual Meeting of the Society for Medical Decision Making, October 23-26, 2016, Vancouver, Canada.
18. Lavelle T, Messonnier ML, Stokley S, Gebremariam A, Simon NJ, Rose A, **Prosser LA**. Using Conjoint Analysis to Identify Factors that Influence Vaccine Acceptance. Presented at the 38th Annual Meeting of the Society for Medical Decision Making, October 23-26, 2016, Vancouver, Canada.
19. Richardson JS, **Prosser LA**, Messonnier ML. Preferences for Health Economics Presentations Among Vaccine Policy Makers and Researchers. Presented at the 38th Annual Meeting of the Society for Medical Decision Making, October 23-26, 2016, Vancouver, Canada.

20. Richardson JS, Wittenberg E, **Prosser LA**. Health Utilities of Rare Heritable Disorders: Approaches for Health State Descriptions and Measuring Spillover Effects on Family Members. Presented at the 38th Annual Meeting of the Society for Medical Decision Making, October 23-26, 2016, Vancouver, Canada.
21. Richardson JS, Hutton D, **Prosser LA**, King C, Eisenberg D, McCullough J. Medical Costs Associated with Grief and Bereavement. Presented at the 39th Annual Meeting of the Society for Medical Decision Making, 2017, Pittsburgh, PA.
22. Rose A, Elmlblad N, Bridges C, Kim D, **Prosser L**, Hutton D. Attributes important to physicians in the decision to stock adult vaccines. Presented at the National Adult Immunization Summit. 2017. Atlanta, GA.
23. Goodman R, Bridges C, Kim D, Pike J, Rose A, **Prosser L**, Hutton D. Rates of commercial and Medicaid health plan non-payment of adult vaccine dose claims. Presented at the National Adult Immunization Summit. 2017. Atlanta, GA.
24. Pike J, Rose A, **Prosser L**, Hutton D. Patterns of pneumococcal vaccination in incident diabetics. Presented at the National Adult Immunization Summit. 2017. Atlanta, GA.